Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
Positive
Strong cash position of $264 million with runway extended into 2027
Significant revenue increase to $34.1 million, up from $7.2 million YoY
Net loss improved to $42.7 million from $59.3 million YoY
Secured $47 million in payments from AstraZeneca partnership